GPR109A/HM74A/HCAR2 polyclonal antibody

Product Specifications

Background

Acts as a high affinity receptor for both nicotinic acid (also known as niacin and (D-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G (i-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

CAS Number

9007-83-4

Structure Composition

1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Product Name Alternative

HCAR2; GPR109A; HCA2; HM74a; HM74b; NIACR1; PUMAG; Puma-g

Swiss Prot

Q8TDS4

Reactivity

Human, Mouse, Rat

Immunogen

A synthetic peptide of human GPR109A/HM74A/HCAR2 (NP_808219.1) .

Conjugation

Unconjugated

Applications

WB, IHC, IF/ICC

Dilution

WB,1:500 - 1:2000|IHC,1:50 - 1:200|IF/ICC,1:50 - 1:200

Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .